Intas Pharma ropes in Dr Vikas Sarangal as Deputy General Manager - Project Management

Published On 2025-06-23 07:30 GMT | Update On 2025-06-23 11:23 GMT

Ahmedabad: Intas Pharma has appointed Dr Vikas Sarangal as Deputy General Manager - Project Management.

Announcing the appointment in a LinkedIn post, Intas stated, "We’re excited to welcome Dr. Vikas Sarangal to Intas Pharmaceuticals as Deputy General Manager – Project Management."

With over 10 years of experience spanning project management, new product development, and competitive intelligence in the pharmaceutical and biotech industries, Dr. Sarangal brings valuable insights and expertise to Intas growing team.

"We look forward to his contributions as we continue driving innovation and delivering on our commitment to a healthier tomorrow," Intas stated.

Read also: Intas Gets CDSCO Panel Nod to Conduct Phase III Trial of Pertuzumab Biosimilar for Breast Cancer

Sharing his enthusiasm, Dr. Sarangal said, "I look forward to accelerating Intas' legacy of project success at Intas by integrating scientific insights with robust execution to drive innovation in critical therapies."

His background includes roles at Molekule Consulting LLC and SmartAnalyst, as well as leadership positions at Cadila Pharmaceuticals, where he served as Senior Manager in both R&D and NPD.

Intas has also appointed Nitin Patel as Associate Vice President - Global Portfolio, Project & Business Development and Dr Rupesh Rane has also been named as Associate Vice President – International Business at Intas Animal Health.

Read also: Intas Pharma appoints Nitin Patel, Dr Rupesh Rane to key leadership roles

Intas is a vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide. Intas is currently investing in a higher barrier to entry developments such as Biosimilar and New Chemical Entities.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Intas Pharma ropes in Dr Vikas Sarangal as Deputy General Manager - Project Management

Similar News

Setback To Novartis: CDSCO Panel Rejects Lanalumab Phase III Trial Design Over Study Flaws

Kerala Medical Services Corporation not procured rabies vaccine without CDL certificate: Health Minister

37 Essential Drugs Including Paracetamol, Atorvastatin To Get Cheaper, NPPA Issues Revised Price List

Over 5 lakh Tramadol, Alprazolam tablets worth Rs 20 crore seized,; 5 arrested

Roche Susvimo maintains vision over five years with two refills per year in people with nAMD

Fire erupts at Dey's Medical plant in Kolkata, no injuries reported

One-shot Dengue vaccine 'DengiAll' completes 70% enrolment of participants in Phase III trial: Centre

Sun Pharma Gets Relief As Delhi HC Bars Use of BERIVITAL, BEZOLIC, DOZE-30 For Trademark Infringement